Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209116 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19628622 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12466620 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL301501 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4203114 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12646402 | 0.94 | FFAR1 (0.73) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1550383 | 0.90 | FFAR1 (1.00) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21845792 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL799523 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16232159 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-01 | — | — | US | disclosed |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS SA (ES) | 2018-05-10 | — | — | US | disclosed |
| US-9944601-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2018-04-17 | — | — | US | disclosed |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
| US-9708309-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2017-07-18 | — | — | US | disclosed |
| US-9670136-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2017-06-06 | — | — | US | disclosed |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2017-01-12 | — | — | US | disclosed |
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2016-12-22 | — | — | US | disclosed |
| US-9487512-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-11-08 | — | — | US | disclosed |
| US-9469597-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-10-18 | — | — | US | disclosed |
| US-9181198-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS S.A. (ES) | 2015-11-10 | — | — | US | disclosed |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-04-30 | — | — | US | disclosed |
| US-9012452-B2 | Processes for making cyclopropyl amide derivatives and intermediates associated therewith | ASTRAZENECA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-01-22 | — | — | US | disclosed |
| US-8853390-B2 | Processes for preparing 1,2-substituted cyclopropyl derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | disclosed |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Fenomics S.A. (ES) | 2013-09-05 | — | — | US | disclosed |
| US-20130172560-A1 | PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH | ASTRAZENECA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2013007621-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2013-01-17 | — | — | WO | disclosed |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | FFAR1 3160/4885ALDH1A1 545/4885CYP1A2 141/4885 |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | FFAR1 2791/4885ALDH1A1 307/4885CYP1A2 181/4885 |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | FFAR1 2820/4885ALDH1A1 261/4885CYP1A2 78/4885 |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | FFAR1 2820/4885ALDH1A1 261/4885CYP1A2 78/4885 |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | FFAR1 3080/4885ALDH1A1 562/4885CYP1A2 148/4885 |
| US-20130172560-A1 | PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH | HRH4, HRH2, HRH3 | FFAR1 63/4885ALDH1A1 398/4885CYP1A2 151/4885 |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | FFAR1 2791/4885ALDH1A1 307/4885CYP1A2 181/4885 |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | PDCD1, PDK3, PDCD1LG2 | FFAR1 119/4885ALDH1A1 135/4885CYP1A2 244/4885 |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | FFAR1 3080/4885ALDH1A1 562/4885CYP1A2 148/4885 |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | HRH3, HRH4, HRH1 | FFAR1 211/4885ALDH1A1 1799/4885CYP1A2 591/4885 |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | FFAR1 3160/4885ALDH1A1 545/4885CYP1A2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.